Silver Grove Financial Group’s Regencell Bioscience RGC Stock Holding History

Silver Grove Financial Group’s Portfolio RGC Stock Details RGC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6	Buy	+1	New	+$24	﹤0.01%	2450

Other funds holding RGC

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Amundi Paris, France $416B AUM 44.19% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

Silver Grove Financial Group's RGC Position: Q2 2026 in Review

Silver Grove Financial Group opened a new position in Regencell Bioscience (RGC) in Q2 2026: 1 share worth $6. The stake represents ﹤0.01% of the portfolio and ranks #2450 among its holdings.

35 funds tracked by Wall St. Rank hold RGC as of Q2 2026.

Silver Grove Financial Group held 1 share of Regencell Bioscience worth $6 as of Q2 2026.
Regencell Bioscience was a new Silver Grove Financial Group position in Q2 2026.
Regencell Bioscience made up ﹤0.01% of Silver Grove Financial Group's portfolio in Q2 2026, its #2450 holding.
35 funds tracked by Wall St. Rank held Regencell Bioscience as of Q2 2026.

Based on Silver Grove Financial Group's 13F filing for Q2 2026, filed 13 Aug 2026.